Kabifungin®

• Empirical therapy for presumed fungal infections in febrile neutropenic patients.
• Treatment of Candidemia and the following Candida infections: Intra-abdominal abscesses, Peritonitis and Pleural space infections.
• Treatment of Esophageal Candidiasis.
• Treatment of invasive Aspergillosis in patients who are refractory to or intolerant of other therapies (i.e amphotericin B, lipid formulations of amphotericin B, and/or itraconazole).
• For Invasive candidiasis fungal infection.
   

• The dosage and duration of Caspofungin treatment for each indication are as follows:

Empirical Therapy for Presumed Fungal Infections in Febrile Neutropenic Patients
Administer a single 70 mg loading dose on Day 1, followed by 50 mg once daily
thereafter. Duration of treatment should be based on the patient's clinical response.
Continue empirical therapy until resolution of neutropenia. In general, treat patients
found to have a fungal infection for a minimum of 14 days after the last positive
culture and continue treatment for at least 7 days after both neutropenia and clinical
symptoms are resolved. If the 50 mg dose is well tolerated but does not provide an
adequate clinical response, the daily dose can be increased to 70 mg.

Candidemia and Other Candida Infections
Administer a single 70 mg loading dose on Day 1, followed by 50 mg once daily
thereafter. Duration of treatment should be dictated by the patient's clinical and
microbiological response. In general, continue antifungal therapy for at least 14 days
after the last positive culture. Patients with neutropenia who remain persistently
neutropenic may warrant a longer course of therapy pending resolution of the
neutropenia.

Esophageal Candidiasis
The dose is 50 mg once daily for 7 to 14 days after symptom resolution. A 70 mg
loading dose has not been studied for this indication. Because of the risk of relapse of
oropharyngeal candidiasis in patients with HIV infections, suppressive oral therapy
could be considered.

Invasive Aspergillosis
Administer a single 70 mg loading dose on Day 1, followed by 50 mg once daily
thereafter. Duration of treatment should be based upon the severity of the patient's
underlying disease, recovery from immunosuppression, and clinical response.
 

• Kabifungin® 50 mg/70 mg is a white compact lyophilized powder in 10 ml tubular glass vial USP Type I, with grey bromobutyl rubber stopper and white flip-off, supplied along with 10 ml sterile water for injections IP.

• Kabifungin® 50

Each vial contains: 
Caspofungin acetate 50 mg
One ampoule containing sterile water for injections IP 10 ml

• Kabifungin® 70

Each vial contains: 
Caspofungin acetate 70 mg
One ampoule containing sterile water for injections IP 10 ml